May 19, 2022
1 min watch
Save
VIDEO: Treatment interval extended with faricimab for diabetic macular edema
Issue: June 25, 2022
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress here, David Eichenbaum, MD, discusses the personalized treatment interval dosing data from the YOSEMITE and RHINE studies of faricimab for DME.
Published by:
Sources/Disclosures
Collapse
Source:
Eichenbaum D. Personalized treatment interval (PTI) dosing dynamics over 2 years in the phase 3 YOSEMITE and RHINE trials of faricimab in diabetic macular edema. Presented at: Retina World Congress; May 12-15, 2022; Fort Lauderdale, Fla.
Disclosures:
Eichenbaum reports being a consultant, speaker and researcher for Genentech/Roche.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.